Item 8.01   Other Events.
Update regarding the B+L Separation and the Solta IPO
On August 6, 2020, Bausch Health Companies Inc. ("BHC" or the "Company")
announced that it intends to separate its eye health business into an
independent publicly traded entity from the remainder of BHC (the "B+L
Separation"). On August 3, 2021, the Company announced its intention to conduct
an initial public offering of its medial aesthetics business, Global Solta (the
"Solta IPO").
BHC today announced that it has previously confidentially submitted draft
registration statements on Form S-1 with the Securities and Exchange Commission
(the "SEC") relating to each of the B+L Separation and the Solta IPO. The number
of common shares to be offered and the price range for the proposed transactions
have not yet been determined. The Company continues to expect the Solta IPO and
the B+L Separation to be completed on previously communicated timelines, subject
to market and other conditions.
This current report on Form 8-K shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of any securities
in any state, province or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the securities
laws of any such state, province or jurisdiction.
Forward-Looking Statements
This current report on Form 8-K contain forward-looking statements, including
with respect to the timing off the Solta IPO and the B+L Separation, and which
involve risks and uncertainties. Readers are cautioned not to place undue
reliance on any of these forward-looking statements. These forward-looking
statements speak only as of the date hereof. BHC undertakes no obligation to
update any of these forward-looking statements to reflect events or
circumstances after the date hereof, unless required by law.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses